Advanced search
Publication Cover
Modern Rheumatology Volume 24, 2014 - Issue 2
Journal homepage
257
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Efficacy and safety of reducing duration of infliximab infusion

Shunsuke FukuyoThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Kazuyoshi SaitoThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Kunihiro YamaokaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Norifumi SawamukaiThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Shintaro HirataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Masao NawataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
,
Shigeru IwataThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
&
Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JapanCorrespondence[email protected]
 show all
Pages 275-280 | Received 11 Jan 2013, Accepted 16 Apr 2013, Published online: 11 Oct 2013

References

  • Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659–72.
  • St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. For the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50(11): 3432–43.
  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. For the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000;343(22):1594–602.
  • Yamanaka H, Tanaka Y, Sekiguchi N, Inoue E, Saito K, Kameda H, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17(1):28–32.
  • Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: 1-year clinical and ragiographic outcomes (RECONFIRM-II). Mod Rheumatol. 2008;18(2):146–52.
  • Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008;18(5):447–54.
  • Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008;18(5):460–4.
  • Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2008;58(2 Suppl):S126–35.
  • Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al. RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010;69(7):1286–91.
  • Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189–94.
  • van Vollenhoven RF, Gullstrom E, Klareskog L. Feasibility of 1 hour infliximab infusions. Ann Rheum Dis. 2005;64(4):654.
  • Buch MH, Bryer D, Lindsay S, Rees-Evans B, Fairclough A, Emery P. Shortening infusion times for infliximab administration. Rheumatology (Oxford). 2006;45(4):485–6.
  • Miyasaka N, Takeuchi T, Eguchi K. Proposed (corrected) Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005;15(1):4–8.
  • Ducourau E, Mulleman D, Goupille P. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011;13(3):105.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.